# UK IVD Contract Manufacturing Market > UK IVD Contract Manufacturing Market Research Report: Size, Share, Trend Analysis By Product Type (Reagents, Diagnostic Devices, Assay Kits, Consumables), By Technology (Molecular Diagnostics, Immunoassays, Clinical Chemistry, Microbiology), By End-user (Hospitals, Diagnostic Laboratories, Research Institutions, Home Care), and By Service Type (Manufacturing Services, Research and Development Services, Packaging Services) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.99% - **2024:** $ 977.4 Million - **2025:** $ 1,094.59 Million - **2035:** $ 3,398 Million - **Key Players:** Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Ortho Clinical Diagnostics (US), Hologic (US) **Report ID:** MRFR/MED/50817-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 10, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-ivd-contract-manufacturing-market-52576 --- ## Market Summary ## **UK IVD Contract Manufacturing Market Overview** As per MRFR analysis, the UK IVD Contract Manufacturing Market Size was estimated at 354.5 (USD Million) in 2023.The UK IVD Contract Manufacturing Market is expected to grow from 371(USD Million) in 2024 to 645 (USD Million) by 2035. The UK IVD Contract Manufacturing Market CAGR (growth rate) is expected to be around 5.156% during the forecast period (2025 - 2035). **Key UK IVD Contract Manufacturing Market Trends Highlighted** Significant trends in the UK IVD Contract Manufacturing Market are being driven by both legislative changes and technological advancements. The growing need for point-of-care testing and personalised treatment, which coincides with the UK's desire for comprehensive healthcare reforms, is a significant market driver. The focus on creating innovative IVD solutions is increased by the National Health Service's (NHS) emphasis on the necessity of quick diagnosis. Furthermore, the UK government's encouragement of medical technology innovation is creating an atmosphere that is favourable to the expansion of the contract manufacturing industry. Specialised diagnostics for infectious diseases is seeing growth, especially in the wake of the last epidemic. As a result, contract manufacturers and biotechnology companies are now working together more frequently to address pressing testing requirements. Furthermore, as regulations continue to change, IVD manufacturers are increasingly required to adhere to new rules set forth by the Medicines and Healthcare Products Regulatory Agency (MHRA). This opens up more opportunities for companies that can guarantee compliance while producing high-quality goods. The production processes are clearly moving towards automation and digital solutions, according to recent developments. Smart technologies are being used by a large number of contract manufacturers in the UK to improve production accuracy and efficiency. This is in line with the larger digital revolution taking place in the UK healthcare sector, where analytics and data integration are playing a key role in enhancing patient outcomes. Since manufacturers are looking at eco-friendly methods to lessen their environmental impact, sustainability is also a key priority. All of these tendencies point to a changing environment for the UK IVD Contract Manufacturing Market, where sustainability, innovation, and compliance are crucial factors influencing potential future developments. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **UK IVD Contract Manufacturing Market Drivers** **Increasing Prevalence of Chronic Diseases** The rise in chronic diseases such as diabetes, cardiovascular diseases, and cancer in the UK is a significant driver for the UK IVD Contract Manufacturing Market. For instance, according to Public Health England, the prevalence of diabetes has risen to approximately 4.5 million people, with projections suggesting a further increase to around 5 million by 2030. This surge in diabetic cases drives a demand for continuous glucose monitoring devices and associated In Vitro Diagnostics (IVD). Leading companies such as Siemens Healthineers and Roche Diagnostics are actively expanding their IVD product lines to cater to this growing patient population. The need for accurate and efficient diagnostic tools is further amplified by the UK's commitment to improve healthcare accountability, particularly following the National Health Service's long-term plan aimed at promoting early diagnosis and intervention. **Technological Advancements in Diagnostics** Technological innovations play a crucial role in the growth of the UK IVD Contract Manufacturing Market. The introduction of next-generation sequencing and point-of-care testing has transformed the diagnostics landscape, enabling faster and more accurate results. The UK Research and Innovation organization has reported significant investment in Research and Development (R&D) for diagnostic technologies, which reached 1.7 billion GBP in funding in 2022. Companies like Abbott Laboratories and Thermo Fisher Scientific are at the forefront of these advancements, further driving demand for contract manufacturing services in the UK. **Regulatory Support and Approval Processes** The UK Government's supportive regulatory environment significantly contributes to the UK IVD Contract Manufacturing Market's expansion. The Medicines and Healthcare products Regulatory Agency has implemented various initiatives to streamline the approval process for new IVD products. These initiatives aim to reduce time-to-market for innovative diagnostic solutions, encouraging greater investment in the sector. A report from the UK Trade and Investment Agency indicated that the life sciences industry, including the IVD market, contributes over 80 billion GBP per year to the UK economy, showcasing the potential growth for contract manufacturers under favorable regulatory frameworks. **UK IVD Contract Manufacturing Market Segment Insights** **IVD Contract Manufacturing Market Product Type Insights** The UK IVD Contract Manufacturing Market segmentation reveals a diverse landscape of product types that play a crucial role in supporting diagnostic and therapeutic advancements within the healthcare sector. Primarily, the market is characterized by various well-defined categories, including Reagents, Diagnostic Devices, Assay Kits, and Consumables, each contributing uniquely to the overall functionality and efficiency of in vitro diagnostics. Reagents are essential components for conducting various assays, significantly impacting the quality and reliability of test results. Their demand is driven by the continuous need for accurate diagnostic solutions, further emphasizing their relevance in disease management and health check-ups. Diagnostic Devices represent another significant aspect of this market, encompassing a wide range of technologies used in medical diagnostics. With the rapid evolution in technology and the increasing importance of early disease detection and monitoring, this product type has witnessed considerable growth. Innovative devices are being developed, making diagnostics more accessible and user-friendly in clinical settings as well as for home-based medical testing. Assay Kits complement this segment by providing ready-to-use solutions that facilitate efficient testing procedures, reducing analysis time and increasing throughput, which is critical for healthcare providers striving to deliver quick and accurate patient care. Consumables, which cover various essential items such as pipettes, vials, and other single-use products, also have a notable share in the market. Their regular usage in laboratories underlines their importance in maintaining hygiene and preventing contamination during testing processes. The continuous advancement in technologies and research methodologies further drives the inclusion of specialized consumables tailored to meet evolving testing requirements. Overall, the segmentation of the UK IVD Contract Manufacturing Market reflects a robust ecosystem wherein each product type not only complements the others but also highlights the market's potential for growth and innovation driven by increasing healthcare demands. Supportive factors such as an aging population, rising prevalence of chronic diseases, and a growing emphasis on preventive care underpin this market's dynamic nature. The collaboration between manufacturers and healthcare providers is essential in developing more effective, accurate, and efficient diagnostic solutions, facilitating improved health outcomes across the UK healthcare system. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **IVD Contract Manufacturing Market Technology Insights** The Technology segment of the UK IVD Contract Manufacturing Market encompasses various crucial areas including Molecular Diagnostics, Immunoassays, Clinical Chemistry, and Microbiology, each playing a significant role in advancing healthcare diagnostics. Molecular Diagnostics is increasingly important due to its ability to provide precise identification of pathogens and genetic variations, thus facilitating personalized medicine. Immunoassays remain vital for their application in numerous routine tests, aiding in disease detection and monitoring. Clinical Chemistry is predominantly focused on analyzing bodily fluids for metabolic functions, allowing comprehensive patient assessments. Microbiology technology is significant for its role in detecting infectious diseases and understanding microbial resistance patterns. The overall trends indicate a growing demand for these technologies, driven by the increasing prevalence of chronic diseases and an aging population in the UK. Furthermore, innovation and Research and Development activities are helping to enhance the efficiency and accuracy of diagnostic tests, thereby aligning with the needs of healthcare providers. The UK IVD Contract Manufacturing Market data reveals that the integration of automation and artificial intelligence is poised to redefine operational efficiencies across these segments, paving the way for future advancements in diagnostic capabilities. **IVD Contract Manufacturing Market****End-user****Insights** The End-user segment of the UK IVD Contract Manufacturing Market is characterized by diverse applications across various settings, including hospitals, diagnostic laboratories, research institutions, and home care environments. Hospitals represent a significant portion of this segment due to their rising need for efficient diagnostic solutions that facilitate quicker patient care and enhance clinical outcomes. Diagnostic laboratories play a crucial role as well since they are pivotal in developing and validating tests, which ensures the reliability of diagnostic results. Research institutions contribute immensely by focusing on innovation in testing methodologies, which drives advancements in the IVD landscape and meets the demand for more precise diagnostics. Additionally, the growing trend of at-home testing solutions is reshaping the market, as patients increasingly prefer the convenience of self-testing over traditional methods. As the UK healthcare system emphasizes preventive care and personalized medicine, the End-user segment is poised to see substantial growth, driven by technological advancements and an increased focus on patient-centric care. Collectively, these factors underscore the importance and dynamic nature of the End-user segment within the UK IVD Contract Manufacturing Market. **IVD Contract Manufacturing Market Service Type Insights** The UK IVD Contract Manufacturing Market has shown a diverse range of Service Types that play a vital role in its overall functioning and growth trajectory. Manufacturing Services are crucial, as they facilitate the production of various in vitro diagnostic devices while adhering to strict regulatory standards, ensuring product quality and reliability. Research and Development services hold significant importance, driving innovation and enabling companies to develop advanced diagnostic solutions tailored to specific market needs. Meanwhile, Packaging Services enhance product integrity and compliance, ensuring that diagnostic tools reach end-users in optimal condition. This segment’s adaptability to advancements in technology and changing market demands is vital, as it helps companies streamline their operations and address the dynamic landscape of the healthcare sector. With increasing healthcare spending in the UK and the rising demand for diagnostic solutions, each of these services contributes to the overall market dynamics, positioning the UK as a competitive player in the global IVD manufacturing arena. The persistent innovations and regulatory adherence within these service types support the continuous evolution of the UK IVD Contract Manufacturing Market. **UK IVD Contract Manufacturing Market Key Players and Competitive Insights** The UK IVD Contract Manufacturing Market is characterized by a dynamic landscape, shaped by ongoing innovations and evolving regulatory frameworks. With a growing demand for in-vitro diagnostic (IVD) products, manufacturers are increasingly focusing on expanding their capabilities to meet the needs of both established and emerging healthcare sectors. The competitive environment is influenced by a mix of longtime market players and new entrants seeking to capitalize on advancements in technology, such as molecular diagnostics and point-of-care testing. As companies vie for market share, strategic partnerships, product differentiation, and compliance with stringent industry standards are paramount for success. The market dynamics are further bolstered by the UK’s robust healthcare infrastructure, which promotes collaboration between contract manufacturers and diagnostic companies. Abbott Laboratories maintains a strong presence within the UK IVD Contract Manufacturing Market, driven by its commitment to innovation and quality. The company has positioned itself as a leader by leveraging its extensive expertise in diagnostic technologies, offering a wide range of IVD products that comply with strict regulatory standards. Abbott Laboratories excels in integrating advanced manufacturing processes, which enhances efficiency and product accuracy. Its established reputation allows the company to foster robust relationships with healthcare providers and laboratories, facilitating the seamless distribution of diagnostic solutions across the UK. The company’s strengths lie in its comprehensive portfolio that addresses various medical needs, alongside its dedication to continuous improvement and investment in R&D, ensuring that it remains competitive in this rapidly evolving industry. Thermo Fisher Scientific also holds a prominent position in the UK IVD Contract Manufacturing Market, recognized for its wide array of products and services tailored to meet diagnostic needs. The company specializes in supplying assay development, antibody production, and molecular diagnostics, catering to diverse customer requirements. Thermo Fisher Scientific has effectively expanded its market presence through strategic mergers and acquisitions, enhancing its capabilities and access to innovative technologies. This has allowed the company to address the increasing demand for rapid and reliable diagnostic solutions in the UK healthcare landscape. With a strong focus on quality control and compliance, Thermo Fisher Scientific’s strengths include its proficiency in providing customized manufacturing solutions that meet varying regulatory demands. The company’s comprehensive service offering not only underscores its commitment to customer satisfaction but also solidifies its competitive edge within the UK IVD market. **Key Companies in the UK IVD Contract Manufacturing Market Include:** - Abbott Laboratories - Thermo Fisher Scientific - Siemens Healthineers - Danaher Corporation - PerkinElmer - Merck Group - Acon Laboratories - Ortho Clinical Diagnostics - BD - Hologic - bioMerieux - Novartis - Fujifilm - Medtronic - Roche Diagnostics **UK IVD Contract Manufacturing****Market****Developments** The UK In Vitro Diagnostic (IVD) Contract Manufacturing Market has witnessed significant developments recently, notably with companies such as Abbott Laboratories and Thermo Fisher Scientific actively expanding their product lines to address the rising demand for diagnostics amid ongoing health challenges. Siemens Healthineers and Danaher Corporation have reported a notable increase in market valuation, reflecting the growing emphasis on innovative diagnostic solutions, which has had a positive impact on the sector. August 2023 marked a milestone with Merck Group's acquisition of a prominent diagnostics company, enhancing their portfolio within the UK market. In previous years, major events included PerkinElmer's expansion of its manufacturing capabilities in July 2022 and BD’s strategic partnership with Hologic in June 2021 to streamline development processes. The UK government continues to support the sector through funding initiatives aimed at advancing Research and Development in diagnostics, ensuring that companies such as Roche Diagnostics and bioMerieux are well-positioned for growth. These developments underline the dynamic nature of the UK IVD Contract Manufacturing Market and its response to evolving healthcare needs. **UK IVD Contract Manufacturing Market Segmentation Insights** **IVD Contract Manufacturing Market Product Type Outlook** - Reagents - Diagnostic Devices - Assay Kits - Consumables **IVD Contract Manufacturing Market Technology Outlook** - Molecular Diagnostics - Immunoassays - Clinical Chemistry - Microbiology **IVD Contract Manufacturing Market End-userOutlook** - Hospitals - Diagnostic Laboratories - Research Institutions - Home Care **IVD Contract Manufacturing Market Service Type Outlook** - Manufacturing Services - Research and Development Services - Packaging Services ## Market Drivers ### Focus on Cost Efficiency Cost efficiency remains a critical driver in the ivd contract-manufacturing market. As healthcare budgets tighten, UK companies are increasingly looking to outsource manufacturing to reduce operational costs. By leveraging the expertise of contract manufacturers, firms can achieve significant savings, estimated at around 20-30% in production costs. This trend is particularly relevant for small to medium-sized enterprises that may lack the resources for in-house manufacturing. The ability to access advanced technologies and skilled labor through contract manufacturing enables these companies to remain competitive in a challenging market. Consequently, the focus on cost efficiency is likely to continue shaping the landscape of the ivd contract-manufacturing market. ### Regulatory Landscape Adaptation The regulatory environment in the UK is evolving, impacting the ivd contract-manufacturing market. Companies must navigate complex regulations to ensure compliance with safety and efficacy standards. The UK government has implemented stringent guidelines that require manufacturers to adhere to high-quality standards, which can be challenging for smaller firms. However, this regulatory landscape also presents opportunities for contract manufacturers who specialize in compliance. By offering expertise in navigating these regulations, contract manufacturers can position themselves as valuable partners in the ivd contract-manufacturing market. This adaptation to regulatory changes is likely to influence the strategies of companies seeking to maintain their market presence. ### Innovation in Product Development Innovation plays a pivotal role in the evolution of the ivd contract-manufacturing market. The UK is witnessing a surge in research and development activities aimed at creating novel diagnostic solutions. This is driven by the need for more precise and rapid testing methods, which are essential in modern healthcare. The market is expected to see an increase in investment, with estimates suggesting that R&D spending in the healthcare sector could reach £5 billion by 2026. As companies collaborate with contract manufacturers to bring innovative products to market, the landscape of the ivd contract-manufacturing market is likely to transform, fostering a culture of continuous improvement and adaptation. ### Rising Demand for Diagnostic Testing The increasing prevalence of chronic diseases and the aging population in the UK are driving the demand for diagnostic testing. This trend is particularly evident in the ivd contract-manufacturing market, where the need for rapid and accurate testing solutions is paramount. According to recent data, the UK healthcare sector is projected to grow by approximately 4.5% annually, which directly influences the ivd contract-manufacturing market. As healthcare providers seek to enhance patient outcomes, the reliance on contract manufacturers for innovative diagnostic solutions is likely to rise. This shift not only supports the development of new products but also allows for the efficient scaling of production to meet market needs. ### Increased Collaboration and Partnerships Collaboration between healthcare providers, research institutions, and contract manufacturers is becoming increasingly prevalent in the UK. This trend is driven by the need for integrated solutions that enhance diagnostic capabilities. The ivd contract-manufacturing market is witnessing a rise in partnerships aimed at co-developing innovative products. Such collaborations can lead to shared resources, knowledge exchange, and accelerated product development timelines. As the market continues to evolve, these partnerships are likely to play a crucial role in driving advancements in diagnostic technologies, ultimately benefiting patients and healthcare providers alike. ## Future Outlook The [IVD Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/ivd-contract-manufacturing-market-22013) is projected to grow at 11.99% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for diagnostics, and regulatory support. **New opportunities:** - Development of customized diagnostic kits for niche markets. Expansion of automation in manufacturing processes to enhance efficiency. Strategic partnerships with biotech firms for innovative product development. By 2035, the market is expected to achieve robust growth, positioning itself as a leader in the diagnostics sector. ## Segment Insights ### By Product Type: Reagents (Largest) vs. Assay Kits (Fastest-Growing) In the UK ivd contract-manufacturing market, the product type segment is primarily dominated by reagents, which hold the largest market share, reflecting their critical role in diagnostic procedures. Following reagents, diagnostic devices also represent a significant portion of the market, catering to both established and emerging diagnostics needs. Assay kits, while smaller in share, are rapidly gaining traction due to the increasing demand for efficient and accurate testing methods. The growth trends for this segment are influenced by technological advancements and the rising prevalence of chronic diseases. As the healthcare industry seeks more effective solutions, the demand for innovative assay kits has surged, positioning them as the fastest-growing category within this sector. Additionally, consumables are experiencing steady demand, particularly as the focus on quality control and standardization in diagnostics strengthens. Reagents (Dominant) vs. Assay Kits (Emerging) Reagents are the dominant player in the UK ivd contract-manufacturing market due to their essential role in the functioning of various diagnostic tests. They are widely utilized across different platforms and are fundamental to the accuracy and reliability of diagnostic results. On the other hand, assay kits are emerging as a valuable alternative, capitalizing on the demand for convenience and speed in laboratory processes. The shift towards personalized medicine and rapid testing solutions further fortifies the position of assay kits, making them integral to meeting evolving healthcare needs. Both segments are responding to dynamic market demands, enhancing their offerings to include more diverse and tailored solutions. ### By Technology: Molecular Diagnostics (Largest) vs. Immunoassays (Fastest-Growing) In the UK ivd contract-manufacturing market, the technology segment is predominantly driven by Molecular Diagnostics, which currently holds the largest market share. This segment benefits from its ability to provide rapid and accurate results for infectious diseases and genetic disorders. On the other hand, Immunoassays, while smaller in share, are catching up quickly due to their increased adoption in point-of-care testing and the rising prevalence of chronic diseases. Growth trends in this segment are significantly influenced by technological advancements and the growing demand for personalized medicine. Molecular Diagnostics is seeing sustained growth due to innovations in PCR technologies and next-generation sequencing. Meanwhile, the rising need for early disease detection and monitoring is propelling the Immunoassays segment, making it the fastest-growing area within the market as manufacturers continue to develop more sensitive and specific tests for various health conditions. Technology: Molecular Diagnostics (Dominant) vs. Immunoassays (Emerging) Molecular Diagnostics stands out in the market with its sophisticated techniques that allow for highly accurate and rapid detection of pathogens and biomarkers, thereby facilitating timely medical decisions. This segment is characterized by continuous innovation and integration of advanced technologies, such as CRISPR and real-time PCR. In contrast, the Immunoassays segment is emerging rapidly, driven by demands for reliable and user-friendly diagnostics solutions. Immunoassays are versatile and widely used in clinical laboratories for various applications. Their adaptability to point-of-care settings and advancements in assay development are propelling their growth. As both segments evolve, their combined advancements contribute significantly to the overall progress in the UK ivd contract-manufacturing market. ### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing) In the UK ivd contract-manufacturing market, hospitals dominate the end-user segment, significantly contributing to the overall market share. Their established infrastructure and continuous demand for diagnostic services allow them to maintain a leading position. On the other hand, diagnostic laboratories are rapidly increasing their market footprint due to advancements in technology and demand for quicker diagnostics, which has made them one of the fastest-growing segments in recent years. Growth trends in this segment are driven by several factors. The increasing need for efficient healthcare solutions has propelled hospitals to invest heavily in contract manufacturing partnerships. Moreover, diagnostic laboratories are experiencing growth fueled by innovative testing methods and a higher prevalence of chronic diseases, positioning them as critical players in the ever-evolving landscape of healthcare diagnostics in the UK. Hospitals (Dominant) vs. Research Institutions (Emerging) Hospitals represent the dominant force in the end-user landscape of the UK ivd contract-manufacturing market, largely due to their essential role in patient care and infrastructure investment. Their extensive facilities and consistent demand for diagnostic devices and tests make them a reliable segment for manufacturers. In contrast, research institutions are emerging as important players, as they drive innovation and development in diagnostic technologies. While they may not have the same immediate market power as hospitals, their focus on research and development enables them to adapt quickly to market needs, creating niche opportunities that contribute to their growth. ### By Service Type: Manufacturing Services (Largest) vs. Research and Development Services (Fastest-Growing) In the UK ivd contract-manufacturing market, Manufacturing Services command the largest share of the market, reflecting the primary focus on producing medical devices, reagents, and diagnostic kits. Research and Development Services, while smaller in share, are experiencing robust expansion as innovation in diagnostics accelerates. The presence of key players driving advancements in technologies further solidifies the manufacturing segment's leading position. Research and Development Services are emerging as the fastest-growing segment, fueled by heightened demand for personalized medicine and rapid technological advancements. This growth is supported by strategic partnerships between contract manufacturers and biotechnology firms aiming to innovate IVD solutions. Regulatory pressures and the need for efficient product development cycles contribute to the rising significance of R&D services within the sector, showcasing the dynamic landscape of the market. Manufacturing Services (Dominant) vs. Research and Development Services (Emerging) Manufacturing Services dominate the UK ivd contract-manufacturing market due to their critical role in delivering high-quality, compliant products essential for diagnostic procedures. Their well-established processes and relationships with suppliers and regulatory bodies ensure reliability. Conversely, Research and Development Services are emerging as a key player in the market, driven by continuous innovation and focus on developing next-generation diagnostic technologies. These services are increasingly vital for companies seeking to differentiate their offerings through unique testing solutions. The interplay between these two segments reflects a comprehensive approach to addressing market demands, emphasizing both efficiency in production and the importance of innovation. ## Competitive Benchmarking The IVD contract-manufacturing market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on operational efficiency. Key players such as Thermo Fisher Scientific (US), Roche Diagnostics (CH), and Abbott Laboratories (US) are at the forefront, each employing distinct strategies to enhance their market positioning. For instance, Thermo Fisher Scientific (US) emphasizes innovation through continuous investment in R&D, aiming to expand its product portfolio and improve manufacturing capabilities. Meanwhile, Roche Diagnostics (CH) focuses on strategic partnerships to enhance its technological offerings, thereby strengthening its competitive edge. Abbott Laboratories (US) is also notable for its aggressive expansion into emerging markets, which appears to be a critical component of its growth strategy, collectively shaping a competitive environment that is both collaborative and competitive. The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure is moderately fragmented, with a mix of large multinational corporations and smaller specialized firms. This fragmentation allows for a diverse range of products and services, while the collective influence of key players drives innovation and sets industry standards. In September 2025, Roche Diagnostics (CH) announced a strategic partnership with a leading AI technology firm to develop advanced diagnostic solutions. This collaboration is expected to enhance Roche's capabilities in personalized medicine, indicating a significant shift towards integrating AI in diagnostic processes. Such a move not only strengthens Roche's product offerings but also positions it as a leader in the rapidly evolving landscape of digital health. In October 2025, Abbott Laboratories (US) launched a new manufacturing facility in the UK, aimed at increasing production capacity for its diagnostic products. This facility is expected to create approximately 200 jobs and enhance Abbott's ability to meet growing demand in the region. The establishment of this facility underscores Abbott's commitment to local manufacturing and supply chain resilience, which is increasingly vital in today's market. In August 2025, Thermo Fisher Scientific (US) acquired a smaller biotech firm specializing in molecular diagnostics. This acquisition is likely to bolster Thermo Fisher's capabilities in the IVD sector, allowing for a more comprehensive product range and improved technological integration. Such strategic moves reflect a broader trend of consolidation within the industry, as companies seek to enhance their competitive positioning through acquisitions. As of November 2025, the competitive trends in the IVD contract-manufacturing market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the need for collaboration to drive innovation and meet evolving customer demands. Looking ahead, competitive differentiation is expected to shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability, suggesting a transformative phase for the industry. ## Recent News & Developments The UK In Vitro Diagnostic (IVD) Contract Manufacturing Market has witnessed significant developments recently, notably with companies such as Abbott Laboratories and Thermo Fisher Scientific actively expanding their product lines to address the rising demand for diagnostics amid ongoing health challenges. Siemens Healthineers and Danaher Corporation have reported a notable increase in market valuation, reflecting the growing emphasis on innovative diagnostic solutions, which has had a positive impact on the sector. August 2023 marked a milestone with Merck Group's acquisition of a prominent diagnostics company, enhancing their portfolio within the UK market. In previous years, major events included PerkinElmer's expansion of its manufacturing capabilities in July 2022 and BD’s strategic partnership with Hologic in June 2021 to streamline development processes. The UK government continues to support the sector through funding initiatives aimed at advancing Research and Development in diagnostics, ensuring that companies such as Roche Diagnostics and bioMerieux are well-positioned for growth. These developments underline the dynamic nature of the UK IVD Contract Manufacturing Market and its response to evolving healthcare needs. ## Report Scope | MARKET SIZE 2024 | 977.4(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1094.59(USD Million) | | MARKET SIZE 2035 | 3398.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.99% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Ortho Clinical Diagnostics (US), Hologic (US) | | Segments Covered | Product Type, Technology, End User, Service Type | | Key Market Opportunities | Integration of advanced automation technologies enhances efficiency in the ivd contract-manufacturing market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the IVD contract-manufacturing market. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What is the current valuation of the UK IVD contract-manufacturing market?** A: The market valuation was $977.4 Million in 2024. **Q: What is the projected market size for the UK IVD contract-manufacturing market by 2035?** A: The market is projected to reach $3398.0 Million by 2035. **Q: What is the expected CAGR for the UK IVD contract-manufacturing market during the forecast period?** A: The expected CAGR is 11.99% from 2025 to 2035. **Q: Which product types are included in the UK IVD contract-manufacturing market?** A: Key product types include Reagents, Diagnostic Devices, Assay Kits, and Consumables. **Q: What were the valuations for Diagnostic Devices in 2024?** A: The valuation for Diagnostic Devices was $300.0 Million in 2024. **Q: Which technology segments are prominent in the UK IVD contract-manufacturing market?** A: Prominent technology segments include Molecular Diagnostics, Immunoassays, Clinical Chemistry, and Microbiology. **Q: What is the valuation range for Clinical Chemistry in 2024?** A: The valuation for Clinical Chemistry ranged from $300.0 Million to $1000.0 Million in 2024. **Q: Who are the key players in the UK IVD contract-manufacturing market?** A: Key players include Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers. **Q: What end-user segments are targeted in the UK IVD contract-manufacturing market?** A: End-user segments include Hospitals, Diagnostic Laboratories, Research Institutions, and Home Care. **Q: What services are offered in the UK IVD contract-manufacturing market?** A: Services include Manufacturing Services, Research and Development Services, and Packaging Services. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-ivd-contract-manufacturing-market-52576*